Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Dec 18;9(12):922.
doi: 10.3390/antibiotics9120922.

Gram-Negative Bloodstream Infection: Implications of Antimicrobial Resistance on Clinical Outcomes and Therapy

Majdi N Al-Hasan  1   2
Affiliations
Editorial

Gram-Negative Bloodstream Infection: Implications of Antimicrobial Resistance on Clinical Outcomes and Therapy

Majdi N Al-Hasan. Antibiotics (Basel). .

Abstract

The age- and sex-adjusted incidence rate of Gram-negative bloodstream infection (GN-BSI) is 84 [...].

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

References

    1. Al-Hasan M.N., Eckel-Passow J.E., Baddour L.M. Recurrent Gram-negative bloodstream infection: A 10-year population-based cohort study. J. Infect. 2010;61:28–33. doi: 10.1016/j.jinf.2010.03.028. - DOI - PMC - PubMed
    1. Kadri S.S., Adjemian J., Lai Y.L., Spaulding A.B., Ricotta E., Prevots D.R., Palmore T.N., Rhee C., Klompas M., Dekker J.P., et al. National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH–ARORI). Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: Retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin. Infect. Dis. 2018;67:1803–1814. doi: 10.1093/cid/ciy378. - DOI - PMC - PubMed
    1. Kadri S.S., Lai Y.L.E., Ricotta E.E., Strich J.R., Babiker A., Rhee C., Klompas M., Dekker J.P., Powers J.H., III, Danner R.L., et al. External validation of difficult-to-treat resistance prevalence and mortality risk in Gram-negative bloodstream infection using electronic health record data from 140 US hospitals. Open Forum Infect. Dis. 2019;6:ofz110. doi: 10.1093/ofid/ofz110. - DOI - PMC - PubMed
    1. Kadri S.S., Lai Y.L., Warner S., Strich J.R., Babiker A., Ricotta E.E., Demirkale C.Y., Dekker J.P., Palmore T.N., Rhee C., et al. Forming the National Insititutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH-ARORI). Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: A retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect. Dis. 2020 doi: 10.1016/S1473-3099(20)30477-1. - DOI - PMC - PubMed
    1. Cain S.E., Kohn J., Bookstaver P.B., Albrecht H., Al-Hasan M.N. Stratification of the impact of inappropriate empirical antimicrobial therapy for Gram-negative bloodstream infections by predicted prognosis. Antimicrob. Agents Chemother. 2015;59:245–250. doi: 10.1128/AAC.03935-14. - DOI - PMC - PubMed

Publication types

LinkOut - more resources